Cardiol Therapeutics Inc. - CRDL Business Value to Revenue

Public company logo of Cardiol (CRDL)

Can the cannabidiol-based drug pipeline for combating myocarditis deliver a breakthrough? Cardiol Therapeutics (CRDL) maintains high brand authority within the cardiology community, confirming the scientific potential of the development. The issuer's revenues rely on research grants and commercialization funds. The enterprise value-to-annual revenue multiple visualizes the asset's market valuation, and 0.00 captures the magnitude of this parameter.

Cardiol Therapeutics Inc. (CRDL): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

CRDL (Cardiol Therapeutics): analytical breakdowns and indicator data

- stock price and consensus target price:
- issuer market value details:
Fundamental company valuation:CRDL, Cardiol Therapeutics
Mass-produced product of Cardiol

To separate fundamental stability from market noise, the ratio of enterprise value to annual revenue is used, allowing for an assessment of the asset's real price without the influence of leverage. An analysis of the EV/Sales multiple helps determine the overvaluation of Cardiol Therapeutics (CRDL), whose capitalization relies on the uniqueness of the CardiolRx drug for combating heart inflammation.